Skip to main content
Yabao Pharmaceutical Group Co.,Ltd logo

Yabao Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600351 ISIN · CNE000001CM5 LEI · 65560071PKRS4UHMVU53 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,362 across all filing types
Latest filing 2021-12-22 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600351

About Yabao Pharmaceutical Group Co.,Ltd

http://www.yabao.com.cn

Yabao Pharmaceutical Group Co.,Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceutical products. The company maintains a specialized portfolio across therapeutic areas including pediatrics, cardiovascular health, and endocrinology. Key offerings include traditional Chinese medicines, chemical drugs, and innovative transdermal patches, such as the Dinggui Erqi Patch. The organization operates integrated production bases and research facilities dedicated to advancing drug delivery systems and biotechnological applications. Its business model emphasizes the modernization of traditional therapies alongside the development of conventional pharmaceuticals to address diverse clinical needs.

Recent filings

Filing Released Lang Actions
亚宝药业集团股份有限公司关于公司药品通过仿制药一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval of a pharmaceutical product (甲钴胺片) passing a generic drug consistency evaluation by the National Medical Products Administration of China. It includes details about the drug, regulatory approval, sales data, and risk warnings. The document is short (1175 characters) and serves as a formal public notice of regulatory approval and related information. It does not contain financial statements, audit information, management discussion, or detailed financial data. It is not an annual or interim report, earnings release, or any form of financial filing. It is also not a meeting material or voting result. The content fits best with a Regulatory Filing (RNS) as a general regulatory announcement and compliance document that does not fit other specific categories.
2021-12-22 Chinese
亚宝药业集团股份有限公司简式权益变动报告书（修订版）
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report." It details the change in shareholding by a specific shareholder (广东晋亚纾困股权投资合伙企业) in 亚宝药业集团股份有限公司, including the number of shares held before and after the change, the method of share reduction (block trades and auction trades), and the relevant dates. The document includes detailed information about the shareholder, the shareholding percentages, and the legal compliance statements. There is no indication that this is a full annual or interim financial report, audit report, or earnings release. It is clearly a notification of a change in major shareholding or equity interest. According to the filing definitions, this fits the category of "Major Shareholding Notification (Code: MRQ)" which covers notifications of changes in significant share ownership levels crossing thresholds. The document length and detail confirm it is the report itself, not just an announcement of a report publication or a regulatory filing. Therefore, the correct classification is MRQ with high confidence.
2021-12-15 Chinese
亚宝药业集团股份有限公司关于简式权益变动报告书的更正公告
Major Shareholding Notification Classification · 95% confidence The document is a correction announcement regarding a previously disclosed Simplified Equity Change Report (简式权益变动报告书) by a shareholder (information disclosure obligor). It corrects statements about the shareholder's plan to reduce holdings in the next 12 months. The document is short (825 characters) and serves as a correction notice rather than the original equity change report itself. This fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes or corrections in significant share ownership disclosures.
2021-12-15 Chinese
亚宝药业集团股份有限公司简式权益变动报告书
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report." It details the change in shareholding by an entity named Guangdong Jinya Rescue Equity Investment Partnership in the company 亚宝药业集团股份有限公司 (Yabao Pharmaceutical Group Co., Ltd.). The document includes specifics about the number of shares held before and after the change, the method of share reduction (block trades and auction trades), the period of share transactions, and declarations about compliance with relevant securities laws and regulations. It also references the Chinese Securities Law and related disclosure rules. The content is focused on reporting a change in significant shareholding and the reduction of shares held by a major shareholder. This matches the definition of "Major Shareholding Notification (Code: MRQ)" which involves notification of changes in significant share ownership levels crossing thresholds. The document is not an announcement of a report publication, nor is it a full financial report or management information. It is a formal disclosure of shareholding changes as required by securities regulations.
2021-12-14 Chinese
亚宝药业集团股份有限公司关于持股5%以上股东权益变动的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement regarding a change in shareholding by a shareholder who held more than 5% of the company's shares but has reduced their stake below that threshold. It details the shareholder's identity, the reduction in shares, and confirms that this change does not affect control of the company. The document is titled as a "提示性公告" (prompting announcement) about a shareholder's equity change exceeding 5%. There is no financial data, no report attached, no management discussion, or other report content. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds.
2021-12-14 Chinese
亚宝药业集团股份有限公司股东集中竞价减持股份结果公告
Major Shareholding Notification Classification · 95% confidence The document is a formal announcement regarding the results of a shareholder's concentrated bidding share reduction plan. It details the shareholder's holdings before and after the reduction, the number of shares reduced, the reduction period, and confirms the completion of the reduction plan. There is no indication of it being a full financial report, audit, or management discussion. It is not a voting result or a dividend notice. The content fits the description of a Major Shareholding Notification, as it reports a change in significant share ownership levels crossing the 5% threshold.
2021-12-14 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.